BriaCell Therapeutics Corp. Files 8-K
Ticker: BCTXZ · Form: 8-K · Filed: Oct 1, 2024 · CIK: 1610820
Sentiment: neutral
Topics: corporate-filing, pharmaceuticals
Related Tickers: BCTX
TL;DR
BriaCell Therapeutics filed an 8-K on Oct 1st, former Ansell Capital.
AI Summary
BriaCell Therapeutics Corp. filed an 8-K on October 1, 2024, reporting other events and financial statements. The company, formerly known as Ansell Capital Corp. until June 13, 2014, is incorporated in British Columbia and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing provides an update on the company's corporate activities and financial reporting, which is important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, indicating no immediate significant events or changes.
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Registrant
- Ansell Capital Corp. (company) — Former company name
- October 1, 2024 (date) — Date of report
- June 13, 2014 (date) — Date of name change
- British Columbia (jurisdiction) — State of incorporation
FAQ
What is the primary business of BriaCell Therapeutics Corp.?
BriaCell Therapeutics Corp. operates in the Pharmaceutical Preparations sector, as indicated by its SIC code [2834].
When did BriaCell Therapeutics Corp. change its name?
The company changed its name from Ansell Capital Corp. on June 13, 2014.
What is the filing date of this 8-K report?
The 8-K report was filed on October 1, 2024.
Where is BriaCell Therapeutics Corp. incorporated?
BriaCell Therapeutics Corp. is incorporated in British Columbia.
What is the principal executive office address of BriaCell Therapeutics Corp.?
The principal executive office is located at Suite 300 - 235 15th Street West Vancouver, BC V7T 2X1.
Filing Stats: 455 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-10-01 16:02:31
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 20KB
- ex99-1_001.jpg (GRAPHIC) — 18KB
- ex99-1_002.jpg (GRAPHIC) — 54KB
- ex99-1_003.jpg (GRAPHIC) — 160KB
- 0001493152-24-039016.txt ( ) — 603KB
- bctx-20241001.xsd (EX-101.SCH) — 4KB
- bctx-20241001_def.xml (EX-101.DEF) — 29KB
- bctx-20241001_lab.xml (EX-101.LAB) — 36KB
- bctx-20241001_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated October 1, 2024 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRIACELL THERAPEUTICS CORP. /s/ William V. Williams October 1, 2024 William V. Williams President and Chief Executive Officer